{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:18Z","timestamp":1792787838998,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001951","name":"Angelman Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001951","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Angelman Syndrome Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent progress in the development of genetic therapies promises that impactful treatments for single-gene neurodevelopmental disorders are imminent. But can derailed neurodevelopmental processes be mended after broken genes are replaced or otherwise restored? The results of ongoing clinical trials for Angelman syndrome will soon yield answers to this pressing question, yet the trials face significant obstacles. Here we identify insights needed to aid the quest for a disease-modifying Angelman syndrome therapy, which could serve as a roadmap for the expeditious development of genetic therapies for other single-gene neurodevelopmental disorders.<\/jats:p>","DOI":"10.1186\/s11689-026-09681-5","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:53:39Z","timestamp":1772877219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Crossing the finish line towards a disease-modifying treatment for Angelman syndrome"],"prefix":"10.1186","volume":"18","author":[{"given":"Matthew C.","family":"Judson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Pereira","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca D.","family":"Burdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stormy J.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Deverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Distel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jalazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nespeca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Scheffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Zylka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ype","family":"Elgersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Philpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"9681_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrneurol.2016.133","volume":"12","author":"K Buiting","year":"2016","unstructured":"Buiting K, Williams C, Horsthemke B. Angelman syndrome - insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016;12:584\u201393. https:\/\/doi.org\/10.1038\/nrneurol.2016.133.","journal-title":"Nat Rev Neurol"},{"key":"9681_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ajmg.a.61940","volume":"185","author":"I den Besten","year":"2021","unstructured":"den Besten I, et al. Clinical aspects of a large group of adults with Angelman syndrome. Am J Med Genet A. 2021;185:168\u201381. https:\/\/doi.org\/10.1002\/ajmg.a.61940.","journal-title":"Am J Med Genet A"},{"key":"9681_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/hmg\/ddab050","volume":"30","author":"SNV Bossuyt","year":"2021","unstructured":"Bossuyt SNV, et al. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations. Hum Mol Genet. 2021;30:430\u201342. https:\/\/doi.org\/10.1093\/hmg\/ddab050.","journal-title":"Hum Mol Genet"},{"key":"9681_CR4","doi-asserted-by":"publisher","first-page":"41208","DOI":"10.1074\/jbc.M401302200","volume":"279","author":"EM Cooper","year":"2004","unstructured":"Cooper EM, Hudson AW, Amos J, Wagstaff J, Howley PM. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J Biol Chem. 2004;279:41208\u201317. https:\/\/doi.org\/10.1074\/jbc.M401302200.","journal-title":"J Biol Chem"},{"key":"9681_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1006\/geno.2001.6543","volume":"73","author":"SJ Chamberlain","year":"2001","unstructured":"Chamberlain SJ, Brannan CI. The Prader-Willi syndrome imprinting center activates the paternally expressed murine Ube3a antisense transcript but represses paternal Ube3a. Genomics. 2001;73:316\u201322. https:\/\/doi.org\/10.1006\/geno.2001.6543.","journal-title":"Genomics"},{"key":"9681_CR6","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/hmg\/dds130","volume":"21","author":"L Meng","year":"2012","unstructured":"Meng L, Person RE, Beaudet AL. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. Hum Mol Genet. 2012;21:3001\u201312. https:\/\/doi.org\/10.1093\/hmg\/dds130.","journal-title":"Hum Mol Genet"},{"key":"9681_CR7","doi-asserted-by":"publisher","first-page":"e27221","DOI":"10.1371\/journal.pone.0027221","volume":"6","author":"JL Daily","year":"2011","unstructured":"Daily JL, et al. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. PLoS ONE. 2011;6:e27221. https:\/\/doi.org\/10.1371\/journal.pone.0027221.","journal-title":"PLoS ONE"},{"key":"9681_CR8","doi-asserted-by":"publisher","unstructured":"Judson MC, et al. Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice. JCI Insight. 2021;6. https:\/\/doi.org\/10.1172\/jci.insight.144712.","DOI":"10.1172\/jci.insight.144712"},{"key":"9681_CR9","doi-asserted-by":"publisher","first-page":"102899","DOI":"10.1016\/j.conb.2024.102899","volume":"88","author":"JC Krzeski","year":"2024","unstructured":"Krzeski JC, Judson MC, Philpot BD. Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome. Curr Opin Neurobiol. 2024;88:102899. https:\/\/doi.org\/10.1016\/j.conb.2024.102899.","journal-title":"Curr Opin Neurobiol"},{"key":"9681_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13229-024-00636-y","volume":"15","author":"SS Ozarkar","year":"2024","unstructured":"Ozarkar SS, et al. Comparative profiling of white matter development in the human and mouse brain reveals volumetric deficits and delayed myelination in Angelman syndrome. Mol Autism. 2024;15:54. https:\/\/doi.org\/10.1186\/s13229-024-00636-y.","journal-title":"Mol Autism"},{"key":"9681_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/s0896-6273(00)80596-6","volume":"21","author":"YH Jiang","year":"1998","unstructured":"Jiang YH, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998;21:799\u2013811. https:\/\/doi.org\/10.1016\/s0896-6273(00)80596-6.","journal-title":"Neuron"},{"key":"9681_CR12","doi-asserted-by":"publisher","unstructured":"Lee D, et al. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome. Elife. 2023;12. https:\/\/doi.org\/10.7554\/eLife.81892.","DOI":"10.7554\/eLife.81892"},{"key":"9681_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neuroscience.2020.02.017","volume":"445","author":"DC Rotaru","year":"2020","unstructured":"Rotaru DC, Mientjes EJ, Elgersma Y. Angelman Syndrome: From Mouse Models to Therapy. Neuroscience. 2020;445:172\u201389. https:\/\/doi.org\/10.1016\/j.neuroscience.2020.02.017.","journal-title":"Neuroscience"},{"key":"9681_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1172\/JCI120816","volume":"129","author":"B Gu","year":"2019","unstructured":"Gu B, et al. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice. J Clin Invest. 2019;129:163\u20138. https:\/\/doi.org\/10.1172\/JCI120816.","journal-title":"J Clin Invest"},{"key":"9681_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13229-018-0231-7","volume":"9","author":"M Sonzogni","year":"2018","unstructured":"Sonzogni M, et al. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants. Mol Autism. 2018;9:47. https:\/\/doi.org\/10.1186\/s13229-018-0231-7.","journal-title":"Mol Autism"},{"key":"9681_CR16","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1523\/JNEUROSCI.2828-17.2018","volume":"38","author":"MS Sidorov","year":"2018","unstructured":"Sidorov MS, et al. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome. J Neurosci. 2018;38:2671\u201382. https:\/\/doi.org\/10.1523\/JNEUROSCI.2828-17.2018.","journal-title":"J Neurosci"},{"key":"9681_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/aur.2267","volume":"13","author":"A Dodge","year":"2020","unstructured":"Dodge A, et al. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion. Autism Res. 2020;13:397\u2013409. https:\/\/doi.org\/10.1002\/aur.2267.","journal-title":"Autism Res"},{"key":"9681_CR18","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1172\/JCI80554","volume":"125","author":"S Silva-Santos","year":"2015","unstructured":"Silva-Santos S, et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Invest. 2015;125:2069\u201376. https:\/\/doi.org\/10.1172\/JCI80554.","journal-title":"J Clin Invest"},{"key":"9681_CR19","doi-asserted-by":"publisher","unstructured":"Sonzogni M, et al. Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes. Mol Autism. 2019;10. https:\/\/doi.org\/10.1186\/s13229-019-0277-1.","DOI":"10.1186\/s13229-019-0277-1"},{"key":"9681_CR20","doi-asserted-by":"publisher","unstructured":"Myers LS et al. A preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition. bioRxiv, 2025.2003.2004.641215, https:\/\/doi.org\/10.1101\/2025.03.04.641215 (2025).","DOI":"10.1101\/2025.03.04.641215"},{"key":"9681_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41583-023-00675-z","volume":"24","author":"P Vanderhaeghen","year":"2023","unstructured":"Vanderhaeghen P, Polleux F. Developmental mechanisms underlying the evolution of human cortical circuits. Nat Rev Neurosci. 2023;24:213\u201332. https:\/\/doi.org\/10.1038\/s41583-023-00675-z.","journal-title":"Nat Rev Neurosci"},{"key":"9681_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00582-1","author":"HO Bazick","year":"2025","unstructured":"Bazick HO, James LM, Taylor-Blake B, Wolter JM, Zylka MJ. Multi-targeting zinc finger nuclease vector unsilences paternal UBE3A in a mouse model of Angelman syndrome. Gene Ther. 2025. https:\/\/doi.org\/10.1038\/s41434-025-00582-1.","journal-title":"Gene Ther"},{"key":"9681_CR23","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ymthe.2024.02.004","volume":"32","author":"MT Clarke","year":"2024","unstructured":"Clarke MT, et al. Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice. Mol Ther. 2024;32:935\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.004.","journal-title":"Mol Ther"},{"key":"9681_CR24","doi-asserted-by":"publisher","first-page":"eabf4077","DOI":"10.1126\/scitranslmed.abf4077","volume":"15","author":"SV Dindot","year":"2023","unstructured":"Dindot SV, et al. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci Transl Med. 2023;15:eabf4077. https:\/\/doi.org\/10.1126\/scitranslmed.abf4077.","journal-title":"Sci Transl Med"},{"key":"9681_CR25","doi-asserted-by":"publisher","unstructured":"Jagasia R et al. Angelman syndrome patient neuron screen identifies a potent and selective clinical ASO targeting <em>UBE3A-ATS<\/em> with long lasting effect in cynomolgus monkey. bioRxiv, 2022.2006.2009.495066, https:\/\/doi.org\/10.1101\/2022.06.09.495066 (2022).","DOI":"10.1101\/2022.06.09.495066"},{"key":"9681_CR26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.ymthe.2023.02.015","volume":"31","author":"J Li","year":"2023","unstructured":"Li J, et al. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice. Mol Ther. 2023;31:2286\u201395. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.015.","journal-title":"Mol Ther"},{"key":"9681_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41421-024-00727-3","volume":"10","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Epigenetic editing alleviates Angelman syndrome phenotype in mice by unsilencing paternal Ube3a. Cell Discov. 2024;10:97. https:\/\/doi.org\/10.1038\/s41421-024-00727-3.","journal-title":"Cell Discov"},{"key":"9681_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ymthe.2023.01.013","volume":"31","author":"H O\u2019Geen","year":"2023","unstructured":"O\u2019Geen H, et al. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model. Mol Ther. 2023;31:1088\u2013105. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.013.","journal-title":"Mol Ther"},{"key":"9681_CR29","doi-asserted-by":"publisher","unstructured":"Schmid RS, et al. CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI142574.","DOI":"10.1172\/JCI142574"},{"key":"9681_CR30","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1038\/s41467-024-49788-8","volume":"15","author":"H Vihma","year":"2024","unstructured":"Vihma H, et al. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat Commun. 2024;15:5558. https:\/\/doi.org\/10.1038\/s41467-024-49788-8.","journal-title":"Nat Commun"},{"key":"9681_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","volume":"587","author":"JM Wolter","year":"2020","unstructured":"Wolter JM, et al. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature. 2020;587:281\u20134. https:\/\/doi.org\/10.1038\/s41586-020-2835-2.","journal-title":"Nature"},{"key":"9681_CR32","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s42003-025-08794-2","volume":"8","author":"JM Wolter","year":"2025","unstructured":"Wolter JM, et al. AAV-dCas9 vector unsilences paternal Ube3a in neurons by impeding Ube3a-ATS transcription. Commun Biol. 2025;8:1332. https:\/\/doi.org\/10.1038\/s42003-025-08794-2.","journal-title":"Commun Biol"},{"key":"9681_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s10038-025-01343-z","volume":"70","author":"AM Gunelson","year":"2025","unstructured":"Gunelson AM, et al. Autism and intellectual disability due to a novel gain-of-function mutation in UBE3A. J Hum Genet. 2025;70:439\u201342. https:\/\/doi.org\/10.1038\/s10038-025-01343-z.","journal-title":"J Hum Genet"},{"key":"9681_CR34","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.1038\/s41467-021-27156-0","volume":"12","author":"KP Weston","year":"2021","unstructured":"Weston KP, et al. Identification of disease-linked hyperactivating mutations in UBE3A through large-scale functional variant analysis. Nat Commun. 2021;12:6809. https:\/\/doi.org\/10.1038\/s41467-021-27156-0.","journal-title":"Nat Commun"},{"key":"9681_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/ajmg.1320510109","volume":"51","author":"A Bottani","year":"1994","unstructured":"Bottani A, et al. Angelman syndrome due to paternal uniparental disomy of chromosome 15: a milder phenotype? Am J Med Genet. 1994;51:35\u201340. https:\/\/doi.org\/10.1002\/ajmg.1320510109.","journal-title":"Am J Med Genet"},{"key":"9681_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/0140-6736(91)90278-w","volume":"337","author":"S Malcolm","year":"1991","unstructured":"Malcolm S, et al. Uniparental paternal disomy in Angelman\u2019s syndrome. Lancet. 1991;337:694\u20137. https:\/\/doi.org\/10.1016\/0140-6736(91)90278-w.","journal-title":"Lancet"},{"key":"9681_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1086\/367926","volume":"72","author":"K Buiting","year":"2003","unstructured":"Buiting K, et al. Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with an imprinting defect. Am J Hum Genet. 2003;72:571\u20137. https:\/\/doi.org\/10.1086\/367926.","journal-title":"Am J Hum Genet"},{"key":"9681_CR38","doi-asserted-by":"publisher","unstructured":"Milazzo C, et al. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. JCI Insight. 2021;6. https:\/\/doi.org\/10.1172\/jci.insight.145991.","DOI":"10.1172\/jci.insight.145991"},{"key":"9681_CR39","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41591-025-03784-7","volume":"31","author":"JF Hipp","year":"2025","unstructured":"Hipp JF, et al. The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial. Nat Med. 2025;31:2936\u201345. https:\/\/doi.org\/10.1038\/s41591-025-03784-7.","journal-title":"Nat Med"},{"key":"9681_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/aur.2475","volume":"14","author":"A Dodge","year":"2021","unstructured":"Dodge A, et al. Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity. Autism Res. 2021;14:645\u201355. https:\/\/doi.org\/10.1002\/aur.2475.","journal-title":"Autism Res"},{"key":"9681_CR41","doi-asserted-by":"publisher","first-page":"109132","DOI":"10.1016\/j.ymgme.2025.109132","volume":"145","author":"OS Mabrouk","year":"2025","unstructured":"Mabrouk OS, et al. Novel method for detection of UBE3A protein in CSF from individuals with Angelman syndrome. Mol Genet Metab. 2025;145:109132. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109132.","journal-title":"Mol Genet Metab"},{"key":"9681_CR42","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ajmg.a.38072","volume":"173","author":"A Le Fevre","year":"2017","unstructured":"Le Fevre A, et al. Atypical Angelman syndrome due to a mosaic imprinting defect: Case reports and review of the literature. Am J Med Genet A. 2017;173:753\u20137. https:\/\/doi.org\/10.1002\/ajmg.a.38072.","journal-title":"Am J Med Genet A"},{"key":"9681_CR43","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1093\/hmg\/ddh296","volume":"13","author":"H Nazlican","year":"2004","unstructured":"Nazlican H, et al. Somatic mosaicism in patients with Angelman syndrome and an imprinting defect. Hum Mol Genet. 2004;13:2547\u201355. https:\/\/doi.org\/10.1093\/hmg\/ddh296.","journal-title":"Hum Mol Genet"},{"key":"9681_CR44","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Q Huang","year":"2024","unstructured":"Huang Q, et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science. 2024;384:1220\u20137. https:\/\/doi.org\/10.1126\/science.adm8386.","journal-title":"Science"},{"key":"9681_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1684\/j.1950-6945.2005.tb00095.x","volume":"7","author":"M Galvan-Manso","year":"2005","unstructured":"Galvan-Manso M, Campistol J, Conill J, Sanmarti FX. Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome. Epileptic Disord. 2005;7:19\u201325.","journal-title":"Epileptic Disord"},{"key":"9681_CR46","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/j.1528-1167.2009.02108.x","volume":"50","author":"RL Thibert","year":"2009","unstructured":"Thibert RL, et al. Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia. 2009;50:2369\u201376. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02108.x.","journal-title":"Epilepsia"},{"key":"9681_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ajmg.a.61382","volume":"182","author":"K Bindels-de Heus","year":"2020","unstructured":"Bindels-de Heus K, et al. An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. Am J Med Genet A. 2020;182:53\u201363. https:\/\/doi.org\/10.1002\/ajmg.a.61382.","journal-title":"Am J Med Genet A"},{"issue":"e1516","key":"9681_CR48","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.chembiol.2020.08.017","volume":"27","author":"F Offensperger","year":"2020","unstructured":"Offensperger F, et al. Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP\/UBE3A and Angelman Syndrome-Derived E6AP\/UBE3A Variants. Cell Chem Biol. 2020;27(e1516):1510\u201320. https:\/\/doi.org\/10.1016\/j.chembiol.2020.08.017.","journal-title":"Cell Chem Biol"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-026-09681-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-026-09681-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-026-09681-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:33:40Z","timestamp":1781638420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11689-026-09681-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9681"],"URL":"https:\/\/doi.org\/10.1186\/s11689-026-09681-5","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MDE is an employee of MPM BioImpact, CEO and shareholder of Ascidian Therapeutics and Rhodes Therapeutics, and Board Member and shareholder of Aulos Bioscience, Replicate Bioscience, Orna Therapeutics, and Reunion Neuroscience. MN receives financial compensation from Ionis Pharmaceuticals as a member of an Independent Safety Monitoring Committee for clinical trials of an ASO therapy in Angelman syndrome. BED is a scientific founder of Apertura Gene Therapy. SJC is an employee of F. Hoffmann-La Roche. EJ has received financial compensation from Ionis Pharmaceuticals for participation in an advisory board. BDP is a consultant for Astellas Gene Therapies and has sponsored research agreements with Denali Therapeutics, Ionis Pharmaceuticals, Arbor Biotechnologies, Gondola Bio, and Mahzi Therapeutics. YE is a consultant for Astellas Gene Therapies and has sponsored research agreements with Hoffmann-La Roche, Ionis Pharmaceuticals, and Gondola Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}